Perianal Crohn Disease
6
1
1
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
33.3%
2 terminated out of 6 trials
33.3%
-53.2% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease
The Impact of Perianal Disease on Patient's Sex Life
A Prospective Longitudinal Study of Fecal Microbiome and Calprotectin to Predict Response to Biological Therapy in Patients With CD
Regenerative Therapy With Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cells and Platelet-rich Plasma to Treat Complex Perianal Diseases
Stopping Biological Therapy in PCD Study
SuperSeton Pilot Studie